Physician profile
Da Wang
NPI 1023335882
$2,839.93
in general payments reported to CMS, 2019-2025
13 companies · $916 in 2025
The $916 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $214 · 2021: $47.01 · 2022: $192 · 2023: $126 · 2024: $807 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $695.24 | 2019-2024 | Rexulti |
| Abbvie INC. | $680.54 | 2021-2025 | Vraylar |
| Alkermes, INC. | $327.98 | 2022-2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.00 | 2025 | Caplyta |
| Lundbeck LLC | $166.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $125.00 | 2024 | Spravato |
| Vanda Pharmaceuticals INC. | $116.25 | 2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $69.18 | 2020-2021 | |
| Allergan, INC. | $64.77 | 2020 | |
| Avanir Pharmaceuticals, INC. | $37.59 | 2019 | |
| Indivior INC. | $26.76 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Da Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.